

SIMULTANEOUS SPECTROPHOTOMETRIC ESTIMATION OF ATENOLOL AND LERCANIDIPINE HYDROCHLORIDE IN COMBINED DOSAGE FORM

Mahabal Rashmi H, Deshchougule Sayali G, Suryawanshi Vishnu M, Chabukswar Anuruddha R, Choudhari Vishnu P*, Kuchekar Bhanudas S

Pharmaceutical Analysis and Quality Assurance Department, MAEER's Maharashtra Institute of Pharmacy, MIT Campus, Paud Road, Kothrud, Pune, 411038, MS, India.

Received on : 05.05.2010

Revised : 14.09.10

Accepted : 17.09.10

ABSTRACT

Two simple, rapid, accurate and economic spectrophotometric methods have been developed for the determination of Atenolol (ATE) & Lercanidipine Hydrochloride (LER) in combined dosage form. The first method is Area under curve (AUC) and second is Absorption Corrected method. The wavelength ranges 260-264 & 280-285 were selected to determine Atenolol (ATE) & Lercanidipine (LER), respectively in combined formulation by AUC method. The second method was absorption corrected method in which both the drugs exhibited strong absorbance at 270.33 nm. However, LER exhibited strong absorbance at 353.93, at which ATE showed zero absorbance. Hence, 353.93 nm was selected as one wavelength for determination of LER without interference from ATE. Quantitative estimation of ATE was carried out by subtracting the absorption due to LER at 270.33 nm using experimentally calculated absorption factor. Beer's law was obeyed in the concentration range of 25-300 µg/ml for ATE and 5-60 µg/ml for LER for both the methods. The results of analysis have been validated statistically and recovery studies confirmed the accuracy and reproducibility of the proposed methods which were carried out by following ICH guidelines.

Keywords: *Lercanidipine Hydrochloride; Atenolol; Area under curve; Absorption corrected.*

INTRODUCTION

Atenolol, (RS)-4-(2-Hydroxy-3-isopropylamino-propoxy)phenylacetamide is an analogue of acetamide¹. Atenolol is a selective α_1 receptor antagonist, a drug belonging to the group of β -blockers, a class of drugs used primarily in cardiovascular diseases. Lercanidipine Hydrochloride is 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenyl-propyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride². Lercanidipine is a calcium channel blocker of the dihydropyridine class & is used in the treatment of hypertension.

Literature survey reveals that various methods have been reported for estimation of ATE such as UV spectrophotometry³⁻⁵, reverse phase HPLC, UPLC, HPTLC⁶⁻⁸ individually and in combination dosage form with other drugs. For LER various analytical methods have been reported for its individual estimation and in combined dosage form which includes HPLC, electrophoresis, LC-MS, extractive spectrophotometry, visible spectrophotometry, HPLC with electrochemical detection.⁹⁻¹⁵ Two methods have been reported for simultaneous analysis of ATE and LER in its combination which include TLC- Densitometry and second order derivative spectrophotometry¹⁶⁻¹⁷. Here an attempt has been made to develop simple, rapid and accurate area under curve and absorption

corrected spectroscopic methods¹⁸⁻¹⁹ for simultaneous estimation of ATE and LER from its formulation. The proposed methods are optimized and validated as per International Conference on Harmonization (ICH) guidelines.

Materials and Methods

Instrumentation

An UV-Visible double beam spectrophotometer (Varian Cary 100) with 10 mm matched quartz cells was used for spectrophotometric method. All weighing were done on electronic balance (Model Shimadzu AUW-220D). Spectroscopic grade methanol was used throughout the study. Ultrasonicator (Model 5.5 150H) was used for sample solution preparation.

Reagents and chemicals

Pure drug sample of ATE and LER were kindly supplied as gift sample by Zest Pharma, Indore and Glenmark Pharmaceuticals, Sinnar, Nasik, respectively. These samples were used without further purification. Tablet formulation manufactured by Sun Pharmaceutical Industries (Lotensyl, Batch No. AD 92286) was purchased from local market containing ATE (50 mg) and LER (10 mg) per tablet. Spectroscopy grade methanol purchased from Merck, Mumbai was used throughout the study.

*Correspondence : viraj1404@rediffmail.com

Spectrophotometric method - Atenolol & Lercanidipine

Preparation of Standard Stock Solution

Standard stock solutions of pure drugs containing 1000 µg/ml of ATE and LER were prepared by dissolving separately, 50 mg of each drug in 50 ml methanol.

Preparation of Sample Stock Solution

For formulation analysis, twenty tablets were weighed accurately and a quantity of tablet powder equivalent to 50 mg of ATE + 10 mg of LER was weighed and dissolved in 40 ml of methanol with the aid of ultrasonicator for 10 min and solution was filtered through Whatman paper No. 41 into a 50 ml volumetric flask. Filter paper was washed with methanol, adding washings to the volumetric flask, volume was made up to mark. The solution was suitably diluted with methanol to get of 150 µg/ml of ATE + 30 µg/ml of LER and proposed methods were followed for analysis.

PROCEDURE

Method A: Absorption Corrected Method

Standard solutions of ATE and LER were scanned in spectrum mode from 200 nm to 400 nm at 0.2 band width and 200 nm/min scan rate. The overlain spectrum (Fig.1) of the two drugs indicated that both the drugs exhibited strong absorbance at about 270.33 nm. However LER exhibits strong absorbance at 353.93 nm at which ATE shows zero absorbance. Hence 353.93 nm was selected for the determination of LER without interference of ATE. The linearity range of ATE is 25-300 µg/ml at 353.93 nm with a correlation coefficient of 0.999. LER exhibits linearity over a concentration range of 5-60 µg/ml both at 270.33 nm and at 353.93 nm. The correlation coefficient for LER was found to be 0.999 at both the wavelengths. Absorbance of both the drugs recorded were found to be practically additive at 270.33 nm




Fig. 1: Overlay spectrum of ATE and LER in methanol, ATE (100 µg/ml) and LER (20 µg ml⁻¹)

Mahabal Rashmi H et al

Determination of Absorption Factor at Selected Wavelengths

ATE and LER solution in methanol of known concentrations were scanned against blank on spectrophotometer. The value of absorption factor was found to be 2.19. Quantitative estimation of ATE and LER was carried out using following equation:

$$\text{Corrected Absorbance of ATE at 270.33 nm} = \text{Abs}_{270.33}(\text{ATE} + \text{LER}) - [(\text{abs}_{270.33}(\text{ATE}) / \text{abs}_{353.93}(\text{LER})) \times \text{abs}_{353.93}(\text{LER})] \text{ or}$$

$$\text{Corrected Absorbance of ATE at 270.33 nm} = \text{abs}_{270.33}(\text{ATE} + \text{LER}) - 2.19 \times \text{abs}_{353.93}(\text{LER})$$

Where abs= Absorption value at given wavelength.

Method B: Area under curve

For the simultaneous determination using the Area under curve (AUC) method, suitable dilutions of the standard stock solutions (1000 µg/ml) of ATE and LER were prepared separately in methanol. The solutions of drugs were scanned in the range of 200-400 nm. For Area under curve method, sampling wavelength ranges selected for estimation of ATE and LER were 260-264 nm (ë1-ë2) and 280-285 nm (ë3-ë4) and area were integrated between these selected wavelength ranges for both drugs, which showed linear response with increasing concentration hence the same wavelength range were used for estimation of tablet formulation. By using integrated areas two simultaneous equations (eq. 1 & 2) were constructed and solved to determine concentrations of analytes. Concentration of analytes in mixed standard and the sample solution were calculated using equation (3) and (4).

$$A_1 = 6721 C_{\text{ATE}} + 48975 C_{\text{LER}} \dots \dots \dots (1) \text{ 260-264nm}$$

$$A_2 = 16447 C_{\text{ATE}} + 29479 C_{\text{LER}} \dots \dots \dots (2) \text{ 280-285 nm}$$

$$C_{\text{ATE}} = \frac{A_2 \times a_{y1} - A_1 \times a_{y2}}{a_{x2} \times a_{y1} - a_{x1} \times a_{y2}} \dots \dots \dots (3)$$

$$C_{\text{LER}} = \frac{A_1 a_{x2} - A_2 a_{x1}}{a_{x2} a_{y1} - a_{x1} a_{y2}} \dots \dots \dots (4)$$

Where,

a_{x1} (6721) and a_{x2} (16447) are absorptivities of ATE at (ë1-ë2) and (ë3-ë4) respectively. a_{y1} (48975) and a_{y2} (29479) are absorptivities of LER at (ë1-ë2) and (ë3-ë4) respectively.

A_1 and A_2 are Absorbances of mixed standard at (ë1-ë2) and (ë3-ë4) respectively. C_{ATE} and C_{LER} is the conc. of ATE & LER, respectively in g/100 ml.

Recovery Studies

The accuracy of the proposed methods were checked by recovery study, by addition of standard drug solution to preanalysed sample solution at three different concentration levels (50 %, 100 % and 150 %) within the range of linearity for both the drugs. The basic concentration level of sample solution selected for

Spectrophotometric method - Atenolol & Lercanidipine

spiking of the drugs standard solution was 75 µg/ml of ATE and 15 µg/ml of LER for both the methods.

Precision of the Method

Reparability of the methods were studied by repeating the methods six times. To study intra-day precision, method was repeated 3 times in a day. Similarly the method was repeated on five different days to determine inter-day precision.

RESULTS AND DISCUSSION

Practically no interference from tablet excipients was observed in these methods. As their λ_{max} differ more than 20 nm, absorption corrected method was tried for their simultaneous estimation in formulation. Quantitative estimation of ATE was carried out by subtracting interference of LER using experimentally calculated absorption factor. Both the methods are accurate, simple, rapid, precise, reliable, sensitive and economical.

These methods were validated as per ICH guidelines. The values of % RSD and correlation coefficient were satisfactory. The results of the formulation analysis are presented in Table 1. Result of the recovery study indicates that there is no interference due to excipients present in the formulation. The % Recovery (% RSD) of ATE by Method A and Method B was found to be in the range of 98.9-101(0.33-1.47) and 99.5-100.7(0.35-1.52), respectively and that of LER by Method A and Method B was found to be in the range of 99.2-100.6(1.1-1.56) and 98.4-100.2(1.21-1.6), respectively. Result of precision study summarized in Table 1 indicates that methods are precise.

Table 1: Optical characteristics of the proposed methods and results of formulation

Parameter	ATENLOL		LERCANIDIPINE	
	Method A	Method B	Method A	Method B
λ (nm)	270.33	Area Integrated between 250-264nm	353.9487	Area Integrated between 280-285 nm
Beer's law limit (µg/ml)	25-300	25-300	5-60	5-60
Regression Equation = $mx + c$	Slope (m)	--	0.008859	--
	Intercept (c)	-0.04055	--	-0.023541
Correlation coefficient	0.99988	--	0.99988	--
Precision (%R.S.D.)	Repeatability (n=5)	0.55	0.66	0.76
	Intra-day (3x3 times)	0.57	0.76	0.55
	Inter-day (3x5 days)	0.59	0.87	0.65
	Analysis	0.54	0.72	0.70
Formulation Analysis (% Assay, %RSD) n=5	99.98, 0.84	99.91, 1.01	100.88, 1.1	101.12, 1.24

RSD is relative standard deviation

CONCLUSION

The proposed methods are simple, precise, accurate and rapid for the determination of ATE and LER in combined tablet dosage forms. Analysis of authentic samples containing ATE and LER showed no interference from the common additives and excipients. Hence, recommended procedure is well suited for the

Mahabal Rashmi H et al

assay and evaluation of drugs in pharmaceutical preparations. Thus these methods can be easily and conveniently adopted for routine quality control analysis.

ACKNOWLEDGEMENT

The authors are thankful to Zest Pharma, Indore; Glenmark Pharmaceuticals, Sinnar, Nasik for providing gift samples. The authors are thankful to Management of MAEER's Maharashtra Institute of Pharmacy, Pune for providing necessary facility for the work.

REFERENCES

1. Indian Pharmacopoeia, Ghaziabad: The Indian Pharmacopoeia Commission 2007, p747-748.
2. The Merck Index 14th edn. Whitehouse Station. NJ: Merck & Co. Inc. 2006, p 5445.
3. Bhatia N M, Mohite A S, Bhatia M S. Simultaneous spectrophotometric estimation of atenolol and amlodipine besylate by multi-wavelength method. The Indian Pharmacist. 2007; 6(59): 5962.
4. Kasture A V, Ramteke Madhuri. Simultaneous UV-Spectrophotometric methods for the estimation of atenolol and nifedipine in solid dosage forms. Indian Journal of Pharmaceutical Sciences. 2005; 67(6): 752.
5. Kasture A V, Ramteke Madhuri. Simultaneous UV-spectrophotometric method for the estimation of atenolol and amlodipine besylate in combined dosage form. Indian Journal of Pharmaceutical Sciences. 2006; 68(3):394.
6. Ravi Sankar S, Nanjan M J, Vasudevan M, Shaat N, Suresh B, Sankar SR. Simultaneous estimation of atenolol and amlodipine in formulations by reversed Phase-HPLC. Indian Journal of Pharmaceutical Sciences. 1997; 59(4):171.
7. Durga Rao D, Satyanarayana N V, Sait S S, Ramakoti Reddy Y and Mukkanti K. Simultaneous determination of Losartan potassium, Atenolol and hydrochlorothiazide in pharmaceutical preparation by stability indicating-UPLC. Chromatographia, 2009; 70:647.
8. Argekar A P, Sawant J G. Simultaneous determination of Atenolol and Nitrendipine in pharmaceutical dosage form by HPTLC. Journal of Liquid Chromatography and Related Technologies. 1999; 22(10):1571.
9. Charde S, Kumar L, Saha R. Development and validation of high performance liquid chromatographic method for estimation of lercanidipine in Rabbit serum, Analytical letters. 2007; 40(11):2128.

Spectrophotometric method - Atenolol & Lercanidipine

10. Ab E Enin MS, et al. Spectrophotometric determination of Labetolol and Lercanidipine in pure form and in pharmaceutical preparation using Ferric 1,10 Phenanthroline. *International Journal of Biomedical Sciences*.2009; 15(3):261.
11. Igor Popovik, et al. LC determination of Lercanidipine and its impurities using Drylab software and experimental design procedure .*Chromatographia*. 2008; 67 (5-6): 449.
12. Erk N. Extractive spectrophotometric methods for determination of lercanidipine. *Pharmzie*. 2003 ; 58 (11): 801.
13. Sastry T M, K. Ramkrishna. New Spectrophotometric method for estimation of lercanidipine hydrochloride. *Indian Journal of Chemical Technology*. 2004; 16:431
14. Vijay Kumar M, Muley P R. RP-HPLC determination of Lercanidipine in bulk drug and solid dosage form, *Indian Drugs*, 2004; 41, (1):24-27.
15. Alvarez LA, Pujol S, Squella JA, Nunez -Vergara L J. A selective HPLC with electrochemical method for determination of lercanidipine in tablets. *Journal of Pharmaceutical and Biomedical Analysis*. 2003; 31 (11): 1.

Mahabal Rashmi H et al

16. Bhatia N M, Gavali A Y. Development and validation of method for simultaneous estimation of Atenolol and Lercanidipine from Tablet dosage form by second order derivative method. *Asian Journal of Research in Chemistry*.2009;2(4) :398-400.
17. Deore P V, Shirkhedkar A A, Surana S J. Simultaneous TLC densitometric analysis of Atenolol and Lercanidipine hydrochloride in tablets. *Acta Chromatographia*.2008; 20: 463.
18. Thomas A B, Chavan U B, Nanda R K, Kothapalli L P, Deshpande A D. Simultaneous spectrophotometric estimation of Hydrochlorthiazide, Atenolol and Losartan Potassium in tablet dosage form *Journal of Pharmaceutical Research*. 2009; 8 (3):139.
19. Thomas A B, Chaudhari A A, Nanda R K, Kothapalli L P, Chavan U B, Deshpande A D. Simultaneous spectrophotometric estimation of Enalapril maleate and Losartan Potassium in tablet dosage form.*Journal of Pharmaceutical Research*. 2009; 8 (2): 85.